WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that the Rutgers University Cell and DNA Repository (RUCDR), the largest cell and DNA biobank in the United States, has adopted the Company’s technologies for automation of Next Generation Sequencing (NGS) sample preparation.
Next Generation Sequencing research has the potential to greatly advance knowledge and facilitate data sharing in identifying the causes of disease, in developing potential disease therapies, as well as in possible clinical diagnostic innovations. The combination of PerkinElmer’s sample library automation with Rutgers’ world-renowned biorepository will make millions of biological samples accessible to researchers worldwide, to help enable large-scale genomic and disease-related studies.
The PerkinElmer NGS laboratory pipeline preparation solutions will enable the RUCDR to perform quality control (QC) on 25,000 DNA samples per week, and prepare hundreds of DNA and RNA sequence libraries per week. The products in use include:
Kevin Hrusovsky, president, Life Sciences & Technology, PerkinElmer, said, “PerkinElmer is very proud to be selected by Rutgers for this milestone project in revolutionizing Next Generation Sequencing research. We are excited to be collaborating with a true pioneer in the field of biobanking for NGS as Rutgers makes its millions of samples available to fuel the life sciences research community’s fastest growing and most exciting technique for basic biological research and disease research.”
Dr. Andrew Brooks, associate professor of genetics and chief operating officer, Rutgers University Cell and DNA Repository, said, “Going forward, the RUCDR will have the capacity to prepare every biological sample coming into the repository for automated sequencing applications. This will help expedite research projects, ensure comparable data quality across analytical centers, and facilitate large-scale access and use of clinically-relevant samples across a variety of NIH, foundation and industry funded projects. As preserving prepared libraries of patient samples is becoming a new standard practice for accelerating NGS studies, it is our intention to continue to be the leader in providing researchers with unparalleled access to high quality nucleic acid and cellular material to make potential therapies and diagnostics more powerful and accurate. Without this critical relationship with PerkinElmer, we would not have been able to achieve these goals as efficiently as we have.”
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $1.9 billion in 2011, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Mario Fante, 781-663-5602
Corporate Public Relations Manager
Edelman (on behalf of PerkinElmer, Inc.)
Amanda L. Connolly, 404-832-6785